Related Experiment Video

Updated: May 6, 2026

Modeling Spontaneous Metastatic Renal Cell Carcinoma mRCC in Mice Following Nephrectomy
11:27

Modeling Spontaneous Metastatic Renal Cell Carcinoma mRCC in Mice Following Nephrectomy

Published on: April 29, 2014

16.3K

[Metastatic renal cell carcinoma: primary and follow-up treatment]

T Steiner1, G H Mickisch

  • 1Klinik für Urologie, Helios Klinikum Erfurt GmbH, Nordhäuser Straße 74, 99089, Erfurt, Deutschland, thomas.steiner@helios-kliniken.de.

Der Urologe. Ausg. A
|October 31, 2013
PubMed

Insights

Targeted therapy, including tyrosine kinase inhibitors, offers improved survival for metastatic renal cell carcinoma patients. Current guidelines recommend tyrosine kinase inhibitors as first-line treatment, with ongoing research into new approaches.

Area of Science:

  • Oncology
  • Medical treatment

Background:

  • Systemic treatment for metastatic renal cell carcinoma (mRCC) has significantly evolved.
  • Targeted therapies offer improved survival and quality of life for patients with incurable mRCC.

Purpose of the Study:

  • To review recent advancements in systemic treatment for mRCC.
  • To discuss the role of targeted therapies and current treatment guidelines.

Main Methods:

  • Review of prospective clinical trials evaluating tyrosine kinase inhibitors (TKIs) and mTOR inhibitors.
  • Analysis of current medical guidelines for advanced renal cell carcinoma management.

Main Results:

  • Targeted therapies, including TKIs and mTOR inhibitors, have demonstrated efficacy in mRCC.
  • Current guidelines recommend TKIs as first-line treatment for advanced renal cell carcinoma.
  • The optimal sequence of therapies remains under investigation.

Conclusions:

  • Targeted therapy has transformed mRCC treatment, offering prolonged survival.
  • First-line TKI treatment is supported by recent data.
  • New therapeutic strategies are under active clinical investigation.

More Related Videos

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies06:38

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies

Published on: April 12, 2017

13.0K
Comparing Metastatic Clear Cell Renal Cell Carcinoma Model Established in Mouse Kidney and on Chicken Chorioallantoic Membrane05:36

Comparing Metastatic Clear Cell Renal Cell Carcinoma Model Established in Mouse Kidney and on Chicken Chorioallantoic Membrane

Published on: February 8, 2020

8.5K

Related Concept Videos

Treatment Resistent Cancers02:56

Treatment Resistent Cancers

1.1K
Metastasis02:30

Metastasis

3.3K
Urinary Tract Calculi III: Medical Management01:30

Urinary Tract Calculi III: Medical Management

The diagnosis of renal calculi involves several imaging techniques, including non-contrast CT scans and ultrasound. These methods help visualize kidney stones, assess their size and location, and detect possible obstructions. Additionally, Measuring urine pH is useful for diagnosing specific stone types, such as struvite (alkaline pH) and uric acid stones (acidic pH). Cystine stones are primarily linked to cystinuria, a genetic condition. A urinalysis helps detect blood in the urine (hematuria)...
404
Kidney Transplant II: Surgical Procedure01:26

Kidney Transplant II: Surgical Procedure

Preoperative ManagementThe primary goals of preoperative management in kidney transplantation are to optimize the patient’s metabolic state and prepare them for surgery through diet adjustments, necessary dialysis, and tailored medical treatment. This phase also involves comprehensive infection screening and patient education about the surgical procedure and postoperative care to improve outcomes and adherence.Medical ManagementA comprehensive evaluation is required for both the living...
956